Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder

被引:0
|
作者
Mattingly, Greg W. [1 ]
Childress, Ann C. [2 ]
Cutler, Andrew J. [3 ,4 ]
Estrada, Jose [5 ]
Corliss, Meg [5 ]
机构
[1] Washington Univ, Sch Med, Midwest Res Grp, St Louis, MO 63130 USA
[2] Ctr Psychiat & Behav Med, Las Vegas, NV USA
[3] SUNY Upstate Med Univ, Syracuse, NY USA
[4] Neurosci Educ Inst, Lakewood Ranch, FL USA
[5] Corium LLC, Boston, MA USA
来源
FRONTIERS IN PSYCHIATRY | 2023年 / 14卷
关键词
ADHD; Azstarys; Children's Sleep Habits Questionnaire; dexmethylphenidate; SDX; d-MPH; serdexmethylphenidate; sleep; METHYLPHENIDATE; ADHD;
D O I
10.3389/fpsyt.2023.1193455
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
IntroductionSleep-related problems are common in children with attention-deficit/hyperactivity disorder (ADHD). Sleep disorders are also side effects of all stimulant ADHD medications. Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is a once-daily treatment approved for patients age 6 years and older with ADHD. In this analysis, sleep behavior was assessed during SDX/d-MPH treatment in children with ADHD. MethodsIn a 12-month, dose-optimized, open-label safety study in 6- to 12-year-old participants (NCT03460652), a secondary endpoint was assessment of sleep behavior based on the Children's Sleep Habits Questionnaire (CSHQ) consisting of 8 sleep domains (bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep-disordered breathing, and daytime sleepiness). This post hoc analysis examined the individual sleep domains in the 12-month safety study. ResultsOf 282 participants enrolled, 238 were included in the sleep analysis. At baseline, mean (SD) CSHQ total sleep disturbance score was 53.4 (5.9). After 1 month of treatment, the mean (SD) CSHQ total score significantly decreased to 50.5 (5.4); least-squares mean change from baseline was -2.9 (95% CI: -3.5 to -2.4; p < 0.0001) and remained decreased up to 12 months. Mean sleep-score improvements from baseline to 12 months were statistically significant (p < 0.0001) for 5 of 8 sleep domains, including bedtime resistance, sleep anxiety, night wakings, parasomnias, and daytime sleepiness. Parasomnias and daytime sleepiness sleep domains showed the greatest mean improvement from baseline to 12 months. Sleep onset delay and sleep duration scores increased from baseline to 12 months. No statistically significant worsening occurred from baseline in sleep duration and sleep-disordered breathing domains; however, worsening of sleep onset delay was statistically significant. ConclusionIn this analysis of children taking SDX/d-MPH for ADHD, sleep problems did not worsen based on the mean CSHQ total sleep disturbance score. Statistically significant improvements in most CSHQ sleep domains were observed after 1 month and lasted for up to 12 months of treatment.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Serdexmethylphenidate/dexmethylphenidate capsules for children and adolescents with attention-deficit/hyperactivity disorder (ADHD): a plain language summary
    Kollins, Scott H.
    Marraffino, Andrea
    Cutler, Andrew J.
    Oh, Charles
    Brams, Matthew N.
    Braeckman, Rene
    Childress, Ann C.
    [J]. FUTURE NEUROLOGY, 2024, 19 (01)
  • [2] Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study
    Cutler, Andrew J.
    Kollins, Scott H.
    Brams, Matthew N.
    Corliss, Meg
    Oh, Charles
    Braeckman, Rene
    Childress, Ann C.
    [J]. FRONTIERS IN PSYCHIATRY, 2024, 15
  • [3] Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate
    Childress, Ann C.
    Cutler, Andrew J.
    Patel, Maitrey
    Oh, Charles
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2023, 33 (04) : 134 - 142
  • [4] Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder
    Sugrue, David
    Bogner, Robin
    Ehret, Megan J.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (14) : 1163 - 1170
  • [5] Update on methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder
    Pheils, Jim
    Ehret, Megan J.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (10) : 840 - 849
  • [6] Dexmethylphenidate extended release - In attention-deficit hyperactivity disorder
    Robinson, Dean M.
    Keating, Gillian M.
    [J]. DRUGS, 2006, 66 (05) : 661 - 668
  • [7] Dexmethylphenidate Extended ReleaseIn Attention-Deficit Hyperactivity Disorder
    Dean M. Robinson
    Gillian M. Keating
    [J]. Drugs, 2006, 66 : 661 - 668
  • [8] Sleep disturbances in children with attention-deficit/hyperactivity disorder
    Spruyt, Karen
    Gozal, David
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2011, 11 (04) : 565 - 577
  • [9] Sleep disturbances in children with attention-deficit/hyperactivity disorder
    Corkum, P
    Tannock, R
    Moldofsky, H
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1998, 37 (06): : 637 - 646
  • [10] Sleep disturbances in children with attention-deficit/hyperactivity disorder
    Moreau, V.
    Rouleau, N.
    Morin, C. M.
    [J]. JOURNAL OF SLEEP RESEARCH, 2008, 17 : 47 - 48